1-乙酰基-4-溴-1H-吲唑 | 885698-70-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡唑类
• 中文名称: 1-乙酰基-4-溴-1H-吲唑
• 中文别名: 1-(4-溴吲唑-1-基)乙酮
• 英文名称: 1-(4-bromo-indazol-1-yl)-ethanone
• 英文别名: 1-acetyl-4-bromo-1H-indazole；1-(4-bromoindazol-1-yl)ethanone
• CAS: 885698-70-4
• 化学式: C₉H₇BrN₂O
• 分子量: 239.071
• InChiKey: MZBRBDKGAIDUPD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  13
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  34.9
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 海关编码：
  2933990090
• 储存条件：
  室温且干燥环境下使用。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 1-Acetyl-4-bromo-1h-indazole
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 1-Acetyl-4-bromo-1h-indazole
CAS number: 885698-70-4

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C9H7BrN2O
Molecular weight: 239.1

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen bromide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  1-乙酰基-4-溴-1H-吲唑 在 bis-triphenylphosphine-palladium(II) chloride 、 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride 盐酸 、 potassium acetate 、 碳酸氢钠 作用下， 以 甲醇 、 乙醇 、 水 、 二甲基亚砜 、 甲苯 为溶剂， 反应 48.0h， 生成 4-羟基-2,6-二甲基苯甲腈
  参考文献：
  名称：

  [EN] TREATMENT OF CANCERS HAVING K-RAS MUTATIONS
  [FR] TRAITEMENT DE CANCERS PRÉSENTANT DES MUTATIONS K-RAS

  摘要：

  本发明提供了一种治疗与K-ras突变相关的癌症的方法，适用于需要该方法的受试者。该方法包括以下步骤：(1) 鉴定患有与K-ras突变相关的癌症的受试者；和 (2) 给予该受试者 (i) PI3激酶抑制剂和 (ii) HDAC抑制剂，其中PI3激酶抑制剂和HDAC抑制剂以治疗有效的剂量一起给予。

  公开号：

  WO2011130628A1
• 作为产物：
  描述：

  2,6-二硝基甲苯 在 ammonium sulfide 、 氢溴酸 、 potassium acetate 、 铁粉 、 氯化铵 、 sodium nitrite 作用下， 以 乙醇 、 水 、 甲苯 为溶剂， 反应 13.0h， 生成 1-乙酰基-4-溴-1H-吲唑
  参考文献：
  名称：

  作为 FtsZ 抑制剂的新型 4-溴-1H-吲唑衍生物的合成和抗菌活性

  摘要：

  设计、合成了一系列作为丝状温度敏感蛋白 Z (FtsZ) 抑制剂的新型 4-溴-1H-吲唑衍生物，并测定了它们对各种表型革兰氏阳性菌和革兰氏阴性菌的体外抗菌活性。细胞分裂抑制活性。结果表明，该系列对表皮葡萄球菌和对青霉素敏感的化脓性链球菌的抗菌活性优于其他受试菌株。其中，化合物12和18对耐青霉素金黄色葡萄球菌的活性是3-甲氧基苯甲酰胺（3-MBA）的256倍和256倍，化合物18的活性是3-MBA的64倍，但4-在抑制金黄色葡萄球菌 ATCC29213 方面的活性比环丙沙星弱一倍。特别，化合物 9 对化脓性链球菌 PS 表现出最佳活性 (4 µg/mL)，分别比 3-MBA、姜黄素和环丙沙星的活性高 32 倍、32 倍和 2 倍，但为 4 倍活性低于苯唑西林钠。此外，一些合成的化合物对金黄色葡萄球菌 ATCC25923、大肠杆菌 ATCC25922 和铜绿假单胞菌 ATCC27853 的

  DOI：

  10.1002/ardp.201400412

文献信息

• [EN] TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE<br/>[FR] COMPOSÉS TRICYCLIQUES INHIBITEURS DE PI3K ET PROCÉDÉS D'UTILISATION
  申请人：HOFFMANN LA ROCHE

  公开号：WO2012082997A1

  公开（公告）日：2012-06-21

  Tricyclic PI3k inhibitor compounds of Formula I with anti-cancer activity, anti- inflammatory activity, or immunoregulatory properties, and more specifically with PI3 kinase modulating or inhibitory activity are described. Methods are described for using the tricyclic PI3K inhibitor compounds of Formula I for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, organisms, or associated pathological conditions. Formula I compounds include stereoisomers, geometric isomers, tautomers, and pharmaceutically acceptable salts thereof. The dashed lines indicate an optional double bond, and at least one dashed line is a double bond. The substituents are as described.

  具有抗癌活性、抗炎活性或免疫调节特性的Formula I的三环PI3K抑制剂化合物被描述。描述了使用Formula I的三环PI3K抑制剂化合物进行体外、原位和体内诊断或治疗哺乳动物细胞、生物体或相关病理条件的方法。Formula I化合物包括立体异构体、几何异构体、互变异构体和其药用可接受盐。虚线表示可选的双键，至少有一条虚线是双键。取代基如所述。
• TREATMENT OF CANCERS HAVING K-RAS MUTATIONS
  申请人：Curis, Inc.

  公开号：US20130102595A1

  公开（公告）日：2013-04-25

  The present invention provides a method of treating a cancer associated with a K-ras mutation in a subject in need thereof. The method comprises the steps of: (1) identifying a subject with a cancer associated with a K-ras mutation; and (2) administering to the subject (i) an inhibitor of PI3 kinase and (ii) an HDAC inhibitor, wherein the PI3 kinase inhibitor and the HDAC inhibitor are administered in amounts which together are therapeutically effective.

  本发明提供了一种治疗与K-ras突变相关的癌症的方法，适用于需要该方法的受试者。该方法包括以下步骤：（1）识别患有与K-ras突变相关的癌症的受试者；和（2）向受试者施用（i）PI3激酶抑制剂和（ii）HDAC抑制剂，其中PI3激酶抑制剂和HDAC抑制剂以联合治疗有效的剂量进行施用。
• Pharmaceutical compounds
  申请人：Folkes Adrian

  公开号：US20080076758A1

  公开（公告）日：2008-03-27

  Compounds of Formulae Ia and Ib, and stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting lipid kinases including PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of Formula Ia and Ib for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

  化合物Ia和Ib的结构，以及它们的立体异构体、几何异构体、互变异构体、溶剂合物、代谢产物和药学上可接受的盐，可用于抑制包括PI3K在内的脂质激酶，并用于治疗由脂质激酶介导的癌症等疾病。公开了使用化合物Ia和Ib进行体外、体内和体内诊断、预防或治疗哺乳动物细胞中的这类疾病，或相关的病理状况的方法。
• 亜鉛結合部分を有するホスホイノシチド３−キナーゼインヒビター
  申请人：キュリス,インコーポレイテッド

  公开号：JP2015187145A

  公开（公告）日：2015-10-29

  PROBLEM TO BE SOLVED: To provide phosphoinositide 3-kinase inhibitors with a zinc binding moiety.SOLUTION: There is provided a compound represented by formula (I) in the figure. (X is S, O or the like; Y is CH, N or the like; Gis optionally substituted N or the like; Rand Rare each independently H or the like; C is a substituted heterocycle or the like; B is a linear alkyl or the like; Rand Rtogether with the nitrogen atom coupled to them are morpholino or the like; Gis an indazole ring or the like; q, r and s are independently from 0 to 1, provided that at least one of them is 1; t is from 0 to 1; n is from 0 to 4; and p is from 0 to 2.)

  要解决的问题：提供具有锌结合基团的磷脂酰肌醇3-激酶抑制剂。解决方案：提供了一个由下图中的式（I）表示的化合物。（X为S、O或类似物；Y为CH、N或类似物；G是可选地取代的N或类似物；R和R分别独立地为H或类似物；C为取代的杂环或类似物；B为线性烷基或类似物；R和R与它们结合的氮原子一起是吗啡基或类似物；G是吲唑环或类似物；q、r和s独立地从0到1，但至少其中之一为1；t从0到1；n从0到4；p从0到2。）
• Nickel-Catalyzed Photoredox-Mediated Cross-Coupling of Aryl Electrophiles and Aryl Azides
  作者：Mikhail O. Konev、T. Andrew McTeague、Jeffrey W. Johannes

  DOI：10.1021/acscatal.8b02954

  日期：2018.10.5

  dual catalytic nickel/ruthenium system from aryl azides and aryl electrophiles. Photoreduction of the aryl azide is proposed to proceed through an arylnickel-azide complex, which upon reduction and loss of nitrogen, generates a nickel(III) species capable of facile reductive elimination to afford the desired C–N bond formation. A variety of functionalized (hetero)aryl electrophiles are shown to participate

  通过光氧化还原介导的双催化镍/钌体系，由芳基叠氮化物和芳基亲电试剂制备药用相关的二芳基胺。提议通过芳基镍-叠氮化物配合物进行芳基叠氮化物的光还原，该复合物在氮的还原和损失后会生成能够容易地消除以提供所需的C–N键形成的镍（III）物种。各种官能化的（杂）芳基亲电试剂显示参与偶联，包括碘化物，溴化物，氯化物和三氟甲磺酸酯。该反应易于建立并且在环境条件下进行，不排除氧气或湿气。